These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15782129)

  • 1. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
    Xie Q; Gao CF; Shinomiya N; Sausville E; Hay R; Gustafson M; Shen Y; Wenkert D; Vande Woude GF
    Oncogene; 2005 May; 24(23):3697-707. PubMed ID: 15782129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
    Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
    Miekus K; Kijowski J; SekuĊ‚a M; Majka M
    Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of junction assembly in cultured epithelial cells by hepatocyte growth factor/scatter factor is concomitant with increased stability and altered phosphorylation of the soluble junctional molecules.
    Pasdar M; Li Z; Marreli M; Nguyen BT; Park M; Wong K
    Cell Growth Differ; 1997 Apr; 8(4):451-62. PubMed ID: 9101091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.
    Besser D; Bardelli A; Didichenko S; Thelen M; Comoglio PM; Ponzetto C; Nagamine Y
    Oncogene; 1997 Feb; 14(6):705-11. PubMed ID: 9038378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation.
    Shen Y; Xie Q; Norberg M; Sausville E; Vande Woude G; Wenkert D
    Bioorg Med Chem; 2005 Aug; 13(16):4960-71. PubMed ID: 15978816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells.
    Koga F; Tsutsumi S; Neckers LM
    Cell Cycle; 2007 Jun; 6(11):1393-402. PubMed ID: 17525527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characteristics of HGF-SF and its role in cell motility and invasion.
    Weidner KM; Hartmann G; Naldini L; Comoglio PM; Sachs M; Fonatsch C; Rieder H; Birchmeier W
    EXS; 1993; 65():311-28. PubMed ID: 8380739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.
    Date K; Matsumoto K; Kuba K; Shimura H; Tanaka M; Nakamura T
    Oncogene; 1998 Dec; 17(23):3045-54. PubMed ID: 9881707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met.
    Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH
    J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
    Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
    Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
    Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
    Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
    Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway.
    Paumelle R; Tulasne D; Kherrouche Z; Plaza S; Leroy C; Reveneau S; Vandenbunder B; Fafeur V
    Oncogene; 2002 Apr; 21(15):2309-19. PubMed ID: 11948414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.
    Zhang YW; Su Y; Lanning N; Gustafson M; Shinomiya N; Zhao P; Cao B; Tsarfaty G; Wang LM; Hay R; Vande Woude GF
    Oncogene; 2005 Jan; 24(1):101-6. PubMed ID: 15531925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways.
    Leibowitz-Amit R; Tsarfaty G; Abargil Y; Yerushalmi GM; Horev J; Tsarfaty I
    Cancer Res; 2006 Sep; 66(17):8687-97. PubMed ID: 16951184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
    Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF
    Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.